leisure time -WSS

leisure time

author：entertainment 2025-10-04 07:30:10 - browse：68

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Stories you might have missed in 2023: health, science, medicine

focus

WSS

Biotech incubator Curie.Bio graduates its first startup

The Sacklers, horror, and ‘The Fall of the House of Usher’

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Hospital chaplains balance Covid safety with patients’ spiritual needs

Study: New antibiotic targets gonorrhea as well as last existing drug

Biotech incubator Curie.Bio graduates its first startup

leisure time

leisure time

hotspot

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Cancer drug shortages should be causing more outrage

Stories you might have missed in 2023: health, science, medicine

The cancer drug shortage isn’t new — and neither are the solutions

FDA early review: GLP

Affirmative action in medical school literally saved lives

Arena BioWorks launches in Cambridge to speed drug discovery

Activists slam private health insurers over coverage restrictions

Medicare Advantage overpayments discussion gets experts fired up

entertainment

Diversify hospital leadership teams to protect BIPOC patient health

Extreme heat events are a public health emergency

Sanofi CEO defends move to abandon profit guidance, boost research

FDA early review: GLP

Arena BioWorks launches in Cambridge to speed drug discovery

FDA approves Recor Medical high blood pressure device

focus

entertainment

focus

explore